Research progress of biomarkers for predicting the efficacy of immunotherapy for tumor
10.3760/cma.j.cn371439-20200722-00044
- VernacularTitle:肿瘤免疫治疗疗效预测标志物的研究进展
- Author:
Suyao LI
1
;
Junxing HUANG
Author Information
1. 大连医科大学研究生院 116044
- Keywords:
Neoplasms;
Immunotherapy;
Biomarkers, tumor;
Immunocheckpoint inhibitors
- From:
Journal of International Oncology
2021;48(4):220-224
- CountryChina
- Language:Chinese
-
Abstract:
Immonocheckpoint inhabitors have become the focus of tumor therapy in recent years, and more and more tumor patients benefit from immunotherapy. Due to the high cost of immunotherapy, the benefit rate of immunotherapy for untested population is only 20%. Therefore, accurate selection of predictive biomarkers is crucial for individualized immunotherapy of tumor patients. Biomarkers reflecting tumor immune microenvironment and tumor cell intrinsic features, such as programmed death-1 (PD-1) and its ligand PD-L1, tumor mutational burden and microsatellite instability, have been proved to associate with treatment effect of anti-PD-1/anti-PD-L1 therapy. At the same time, markers based on tissue and serum emerge in endlessly. How to truly achieve accurate immunotherapy for tumor needs further clinical research.
